OXY-1 System

K200109 · Abiomed, Inc. · DTZ · Oct 23, 2020 · Cardiovascular

Device Facts

Record IDK200109
Device NameOXY-1 System
ApplicantAbiomed, Inc.
Product CodeDTZ · Cardiovascular
Decision DateOct 23, 2020
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.4350
Device ClassClass 2
AttributesTherapeutic

Intended Use

The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration

Device Story

OXY-1 System provides extracorporeal circulation for cardiopulmonary bypass (CPB) support up to 6 hours. System components include disposable pump/oxygenator, pump driver, blood tubing, and console. Device inputs: blood flow from patient. Principle of operation: centrifugal pump driven by magnetic coupling; hollow fiber oxygenator with polymethylpentene membrane for gas exchange. Console manages pump speed, gas flow, and monitors system parameters. Used in clinical settings (e.g., OR) by trained perfusionists/clinicians. Output: oxygenated blood returned to patient. Healthcare providers use console display for flow, RPM, and alarm monitoring to manage CPB. Benefits: provides temporary circulatory and respiratory support during cardiac procedures; integrated design reduces bedside equipment footprint.

Clinical Evidence

No clinical data or animal studies were conducted. Substantial equivalence is supported by bench testing, including gas transfer, blood/gas path integrity, hemolysis, hydraulic performance, particulate evaluation, and software verification/validation per FDA guidance for cardiopulmonary bypass oxygenators.

Technological Characteristics

Materials: Polymethylpentene (membrane), Polycarbonate (housing), Urethane (potting), Polyethylene/Sapphire (bearings), PVC (tubing). Centrifugal pump with magnetic coupling. Hollow fiber oxygenator (2.4 m2 surface area). Energy: Battery/Mains. Connectivity: Internal/External gas source. Sterilization: Ethylene Oxide (SAL 10^-6). Standards: IEC 60601-1 (electrical), IEC 60601-1-2 (EMC), ISO 80601-2-69.

Indications for Use

Indicated for patients requiring extracorporeal circulation, including pumping, oxygenation, and carbon dioxide removal during cardiopulmonary bypass procedures lasting up to 6 hours.

Regulatory Classification

Identification

A cardiopulmonary bypass oxygenator is a device used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during open-heart surgery.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions.”

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left side of the logo is the Department of Health & Human Services logo. To the right of the HHS logo is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. October 23, 2020 Abiomed Inc. % Ken Ryder Senior Director Global Regulatory Affairs 1500 John Ave Suite 190 Halethorpe, Maryland 21227 Re: K200109 Trade/Device Name: OXY-1 System Regulation Number: 21 CFR 870.4350 Regulation Name: Cardiopulmonary Bypass Oxygenator Regulatory Class: Class II Product Code: DTZ, KFM, DWA, DWF Dated: September 21, 2020 Received: September 22, 2020 Dear Ken Ryder: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm_identifies_combination product submissions. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see {1}------------------------------------------------ https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531- 542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance)and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Fernando Aguel Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K200109 Device Name OXY-1 System Indications for Use (Describe) The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration | Type of Use (Select one or both, as applicable) | | |-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------| | <div><span style="font-size:12px">☑</span> Prescription Use (Part 21 CFR 801 Subpart D)</div> | <div><span style="font-size:12px">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C)</div> | CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ Product: Oxy-1 System Section: 5 – 510(k) Summary # 510(k) Summary I. SUBMITTER Abiomed, Inc. 22 Cherry Hill Dr. Danvers, MA 01923 Phone: 978-646-1707 Contact Person: J. Kenneth Ryder Date Prepared: October 21, 2020 II. DEVICE Name of Device: OXY-1 System Common or Usual Name: OXY-1 System Classification Name: Cardiopulmonary bypass oxygenator Regulatory Class: II Product Code: DTZ - Oxygenator, Cardiopulmonary Bypass KFM - Pump, Blood, Cardiopulmonary Bypass, Non-Roller Type DWA - Control, Pump Speed, Cardiopulmonary Bypass DWF - Catheter, Cannula and Tubing, Vascular, Cardiopulmonary Bypass III. PREDICATE DEVICE(S) Medtronic Affinity NT (Model 511) Oxygenator (K191029) Maquet, Rotaflow Pump (K991864) Maquet, Rotaflow Console (K991864) Maquet, HLM Tubing Set with Bioline coating (K080592) # IV. DEVICE DESCRIPTION The Breethe® OXY-1 System provides extracorporeal circulation for full or partial cardiopulmonary bypass support for up to six hours. The OXY-1 System includes; a disposable pump and oxygenator, a pump driver, blood tubing, and a console for powering and controlling the pump and managing gas flow. These components are designed to operate together to reduce the overall equipment footprint at the bedside. # V. INDICATION FOR USE The OXY-1 System is indicated for: - OXY-1 System The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration. The identified predicates are indicated for the following: {4}------------------------------------------------ | Product: Oxy-1 System | | | |---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--| | Section: 5 – 510(k) Summary <span style="float:right;">Page 2 of 5</span> | | | | Medtronic - Affinity NT<br>511 (K191029) | The AFFINITY® NT Hollow Fiber Oxygenator with Plasma Resistant Fiber is intended to be<br>used in an extracorporeal perfusion circuit to oxygenate and remove carbon dioxide<br>from the blood and to cool or warm the blood during routine cardiopulmonary bypass<br>procedures up to 6 hours in duration. | | | Maquet - Rotaflow<br>Pump – RF 32<br>(K991864) | The Rotaflow centrifugal pump system is intended for use in an extracorporeal perfusion<br>circuit to pump blood during short duration cardiopulmonary bypass procedures lasting<br>6 hours or less. | | | Maquet - Rotaflow<br>Console (K991864) | The Rotaflow centrifugal pump system is intended for use in an extracorporeal perfusion<br>circuit to pump blood during short duration cardiopulmonary bypass procedures lasting<br>6 hours or less. | | | Maquet - HLM Tubing<br>Set with Bioline coating<br>(K080592) | The HLM Tubing Sets with Bioline Coating are designed to be used in extracorporeal<br>circulation during cardiopulmonary bypass procedures lasting six hours or less. | | The subject device and the identified predicates have the same intended use for extracorporeal circulation during full or partial cardiopulmonary bypass. The Indications for Use for the OXY-1 System is substantially equivalent to the predicate devices. Differences do not alter the intended therapeutic use of the device nor do they affect the safety and effectiveness of the device relative to the predicates. # VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE | Oxygenator Technological<br>Characteristics /<br>Performance Specifications | Subject Device<br>Oxy-1 System (PLU Disposable) | Predicate Device<br>Medtronic - Affinity NT 511 (K191029) | |-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | Materials | | | | Membrane | Polymethylpentene | Polypropylene | | Housing | Polycarbonate | Polycarbonate | | Potting | Urethane | Urethane | | Design | | | | Heat Exchanger | No | Yes | | Membrane Type | Hollow Fiber | Hollow Fiber | | Effective Membrane Surface Area | 2.4 m2 | 2.5 m2 | | Gas Pathway | Two Gas Pathways | Single Gas Pathway | | Oxygenator Geometry | Cylindrical | Cylindrical | | Tubing Connectors | 3/8" | 3/8" | | Priming Volume (Oxygenator Only) | 285 ml | 215 ml | | Sterile | SAL 10^-6 | SAL 10^-6 | | Sterilization method | Ethylene Oxide | Ethylene Oxide | | Performance Specifications | | | | Blood Flow Rate | 0.5-5.0 Lpm | 0.5 - 7.0 Lpm | | Gas Transfer | Tested per "Guidance for Cardiopulmonary Bypass<br>Oxygenators 510(k) Submissions" Dated November<br>13, 2000 | Tested per "Guidance for Cardiopulmonary<br>Bypass Oxygenators 510(k) Submissions" Dated<br>November 13, 2000 | | Hemolysis | Average NIH of 0.0210 mg/100L | Average NIH of 0.0318 mg/100L | | Pressure Drop (at 5 Lpm) | Average of 38 mmHg | Average of 52 mmHg | {5}------------------------------------------------ | Centrifugal Pump<br>Technological<br>Characteristics /<br>Performance Specifications | Subject Device | Predicate Device | |--------------------------------------------------------------------------------------|-------------------------------|------------------------------------------| | | Oxy-1 System (PLU Disposable) | Maquet - Rotaflow Pump - RF 32 (K991864) | | Materials | | | | Housing | Polycarbonate | Polycarbonate | | Impeller | Polycarbonate | Polycarbonate | | Bearing | Polyethylene, Sapphire | Polyethylene, Sapphire | | Design | | | | Pump Operation | Centrifugal pump | Centrifugal pump | | Coupling | Magnetic | Magnetic | | Bearing | Single pivot | Single pivot | | Priming Volume (Pump Only) | 34ml | 32ml | | Tubing Connectors | 3/8" | 3/8" | | Sterile | SAL 10^-6 | SAL 10^-6 | | Sterilization method | Ethylene Oxide | Ethylene Oxide | | Performance Specifications | | | | Blood Flow Rate | 0.5-5.0 Lpm | 0.5 - 9.0 Lpm | | Hemolysis | Average NIH of 0.0210 mg/100L | Average NIH of 0.0318 mg/100L | | Controller & Driver<br>Technological<br>Characteristics /<br>Performance Specifications | Subject Device<br>Oxy-1 System (Console) | Predicate Device<br>Maquet - Rotaflow Console (K991864) | |-----------------------------------------------------------------------------------------|------------------------------------------|---------------------------------------------------------| | Design | | | | Coupling | Magnetic | Magnetic | | Energy Source | Battery / Mains | Battery / Mains | | Other features | | | | Sweep Gas Source | Internal / External | External | | Sighing Gas Source | Internal / External | External | | Software | | | | Constant RPM Mode | Yes | Yes | | Constant Flow Mode | No | Yes | | -Display | | | | --Blood Flow | Yes | Yes | | --Pump RPM Settings | Yes | Yes | | --Internal Sweep Gas Source<br>Settings | Yes | N/A | | --Alarm Limit Settings | Yes | Yes | | -Alarms | | | | --Blood Flow | Yes | Yes | | --Bubble | Yes | Yes | | --Low Battery | Yes | Yes | | --System Failure Alarms | Yes | Yes | | Hardware | | | | -Bubble Sensor | Yes | Yes | | -Flow Sensor | Yes | Yes | | Emergency Drive Unit | Hand Crank | Hand Crank | | Performance Specifications | | | {6}------------------------------------------------ | Controller & Driver<br>Technological<br>Characteristics /<br>Performance Specifications | Subject Device | Predicate Device | |-----------------------------------------------------------------------------------------|----------------|------------------| | RPM Range | 0-4500 RPM | 0-5000 RPM | | Blood Tubing Technological<br>Characteristics /<br>Performance Specifications | Subject Device | Predicate Device | |-------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------| | | Oxy-1 System (PLU Disposable) | Maquet - HLM Tubing Set with Bioline coating<br>(K080592) | | Materials | | | | Tubing | Polyvinyl Chloride | Polyvinyl Chloride | | Surface Treatment | None | Bioline (albumin and heparin) | | Design | | | | Tubing Connectors | 3/8" | 3/8" | #### VII. PERFORMANCE DATA The following performance data was provided in support of the substantial equivalence determination. # Biocompatibility Testing: Biocompatibility testing of the OXY-1 PLU Disposable was conducted for circulating blood for less than 24 hours. # Electrical safety and electromagnetic compatibility (EMC): The system complies with the IEC 60601-1 standard for electrical safety and the IEC 60601-1-2 standard for EMC. # Software Verification and Validation Testing: The software is classified as "major" level of concern. Testing and documentation for a "major" level of concern are provided in the submission. # Performance Testing: The following testing was conducted as recommended in "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions; Final Guidance for Industry and FDA Staff" dated November 13, 2000. - Gas Transfer Testing - Blood and Gas Path Integrity - Hemolysis - Hydraulic Performance - Volatile Organic Compounds - Particulates evaluation - ISO 80601-2-69 - Software V&V - Reliability - Shelf Life No animal studies or clinical studies were required or conducted. {7}------------------------------------------------ Product: Oxy-1 System Section: 5 – 510(k) Summary VIII. CONCLUSIONS The OXY-1 System has the same intended use as the identified predicates, has been demonstrated to be substantially equivalent to the identified predicates through performance testing, and the differences do not raise different questions of safety and effectiveness.
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from the tree

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...